Big medtechs’ efficiency starts to recover from Covid
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
Takeout premiums hold up, but that’s not the whole story
Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.
In a bear market it’s the bad news that matters
The market’s reaction to positive clinical data has largely held up through the downturn, but failures have really, really hurt.
Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Few safe havens surface in another down quarter for biopharma
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
The gloom deepens for biopharma stocks
With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.
Venture investors keep the purse strings tight
Third-quarter numbers show that biopharma venture investments are firmly back in 2018 territory.
No big bang for biopharma buyouts
Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.
